Impaired TM-EPCR-aPC signaling has been observed in various vascular diseases, including atherosclerosis [11–15], but its impact on macrophage function, particularly efferocytosis, in the context of diabetes remains unclear. This evidence concerns the gene PROCR and diabetes mellitus.